国家医保局：支持引导中国创新药高质量发展

Core Viewpoint - The introduction of the "Several Measures to Support the High-Quality Development of Innovative Drugs" aims to address key issues in the development of innovative drugs in China, focusing on a full-chain support system for research, access, hospital use, and multi-payment options [1][2]. Group 1: Measures and Support - The measures include 16 specific actions across five areas to enhance the research and development of innovative drugs, ensuring alignment with clinical treatment needs [2]. - A new payment system for innovative drugs will be established, which includes regular adjustments to the medical insurance catalog and the introduction of commercial health insurance for innovative drugs [2]. - Policies will be implemented to improve the accessibility of innovative drugs, addressing concerns related to their use in various stages such as listing, hospital admission, payment, and distribution [2]. Group 2: Future Actions - The National Healthcare Security Administration and the National Health Commission will implement the measures to support the high-quality development of innovative drugs, ensuring the health rights of the public are better protected [2].